Cannabichromene (CBC) was first isolated in 1966 by Gaoni and Mechoulam — the same researchers who identified THC. It is a phytocannabinoid with the molecular formula C21H30O2, sharing the classic cannabinoid tricyclic structure with THC and CBD but with key differences in its ring system that eliminate its psychoactivity.
Like all major phytocannabinoids, CBC is synthesised from cannabigerol (CBG) — the “mother cannabinoid.” The enzyme CBCA synthase converts CBG-A (cannabigerolic acid) to CBCA (cannabichromenic acid), which then decarboxylates to CBC through heat exposure. This is the same process that converts THCA to THC and CBDA to CBD. In raw cannabis plant material, CBC exists primarily as CBCA; the active CBC is formed through decarboxylation during drying, curing, and especially heating during vaporization or cooking.
CBC’s concentration in cannabis varies significantly by cultivar. In most commercially available high-THC strains, CBC represents less than 1% of total cannabinoid content. However, some cultivars — particularly those with landrace genetics from tropical regions — can contain 3–5% CBC. Industrial hemp strains bred for minor cannabinoid content may contain even higher concentrations.
Unlike THC, CBC is not listed as a controlled substance in most jurisdictions. As a non-intoxicating cannabinoid, it occupies a legal grey area similar to CBD in many countries, and CBC isolate products are beginning to appear in the functional wellness market.
The key to understanding CBC’s non-psychoactive profile is its receptor binding pattern. THC produces its euphoric and intoxicating effects primarily through CB1 receptor agonism in the brain. CBC has very low binding affinity for CB1 receptors — far below the threshold required to produce cognitive impairment or euphoria. This is structurally determined by the different ring geometry compared to THC, which prevents CBC from fitting the CB1 binding pocket in the same way THC does.
CBC’s primary receptor and transporter targets:
CBC’s anti-inflammatory profile is its most extensively studied property. The mechanism operates through several distinct pathways:
One of the primary CBC anti-inflammatory mechanisms involves inhibition of arachidonic acid release from cell membranes. Arachidonic acid is the precursor to prostaglandins and leukotrienes — key inflammatory mediators. By preventing arachidonic acid mobilisation, CBC reduces the upstream substrate for inflammatory cascade amplification without directly blocking COX or LOX enzymes (as NSAIDs do).
This means CBC’s anti-inflammatory mechanism is fundamentally different from standard anti-inflammatory drugs, offering potential complementary activity. The stomach irritation profile of NSAIDs is largely driven by COX inhibition; CBC’s upstream mechanism does not share this adverse effect profile at cannabinoid doses.
TRPA1 and TRPV4 activation by CBC produces anti-inflammatory effects in part through the CGRP (calcitonin gene-related peptide) and substance P pathway — neuroinflammatory mediators that are modulated downstream of TRP channel activation. In inflammatory bowel models, CBC has shown significant anti-inflammatory activity specifically in intestinal tissue, where TRPA1 and CB2 density is high.
One of the most compelling areas of CBC research involves its effects on neural progenitor cell (NPC) viability and proliferation. Neural progenitor cells are adult stem cells in the hippocampus that can differentiate into new neurons — a process called adult neurogenesis. Hippocampal neurogenesis is strongly associated with mood regulation, stress resilience, and learning/memory capacity. Major depression is associated with reduced hippocampal neurogenesis; antidepressant drugs (SSRIs) and exercise both promote it.
Shinjyo and Di Marzo (2013) demonstrated that CBC significantly increased the viability of mouse hippocampal neural progenitor cells and promoted their differentiation. CBC-treated NPCs showed increased survival rates and enhanced differentiation into astrocytes and neurons compared to controls. Crucially, this effect occurred at concentrations achievable within the brain from standard cannabis consumption, making the finding pharmacologically plausible rather than merely academic.
This neurogenic effect may be mediated through CBC’s anandamide reuptake inhibition — elevated anandamide levels are independently associated with increased hippocampal neurogenesis through CB1 receptor signaling. CBC may therefore support neurogenesis through both direct NPC effects and indirect endocannabinoid tone elevation.
The implications for mood and cognitive function are significant but require caution: this research is primarily preclinical (cell culture and animal models). Human neurogenesis evidence remains limited, and extrapolating directly to clinical antidepressant or cognitive-enhancement applications requires further clinical investigation.
Two lines of evidence support CBC’s antidepressant potential: its neurogenic effects (described above) and direct behavioral evidence from animal studies.
Brierley et al. (2016) assessed the antidepressant-like effects of multiple cannabinoids using the forced swim test — a validated animal model for antidepressant activity. CBC produced significant antidepressant-like effects, comparable to fluoxetine (Prozac) at equivalent doses in the model. Notably, the researchers also found that CBC worked synergistically with CBD — the combination produced effects greater than either compound alone, a finding with direct implications for whole-plant cannabis formulations vs. isolates.
The mechanism proposed involves CBC’s combined anandamide elevation (via reuptake inhibition), 5-HT1A modulation (the serotonergic target of buspirone and partially SSRIs), and neurogenic effects creating a multi-modal antidepressant profile that may offer advantages over single-target drug approaches.
Important caveat: forced swim test results do not translate predictably to human antidepressant efficacy, and no CBC-specific human clinical trials for depression exist as of this writing. These findings should be understood as mechanistic evidence supporting further research rather than clinical proof of antidepressant effect.
CBC’s analgesic properties work through TRPA1 channel modulation — a distinct mechanism from THC (CB1-mediated) and CBD (various). This mechanistic independence makes CBC potentially synergistic with both THC and CBD for pain relief.
The most compelling pain evidence is the CBC-THC interaction. Research by DeLong et al. (2010) demonstrated that a CBC-THC combination produced significantly greater pain relief in animal models than either compound alone, with the combination requiring lower total cannabinoid doses to achieve equivalent analgesia. This is a clean entourage effect demonstration: CBC amplifies THC’s analgesic efficacy, which has practical implications for whole-plant medicine dosing vs. THC isolate.
For neuropathic pain specifically, TRPA1 channel activity is particularly relevant — TRPA1 is a primary mediator of neuropathic pain signaling, and CBC’s potent TRPA1 agonism may make it especially useful in neuropathic pain contexts where standard analgesics perform poorly.
| Effect | Evidence Level | Key Study | Mechanism |
|---|---|---|---|
| Anti-inflammatory | Preclinical strong | De Petrocellis 2012; Izzo 2012 | TRP channels, CB2, arachidonic acid |
| Analgesic | Preclinical strong | DeLong et al. 2010 | TRPA1; synergy with THC |
| Neurogenesis | Preclinical (in vitro) | Shinjyo & Di Marzo 2013 | NPC viability, anandamide elevation |
| Antidepressant | Animal models | Brierley et al. 2016 | Anandamide, 5-HT1A, neurogenesis |
| Antimicrobial | In vitro | Appendino et al. 2008 | Membrane disruption (MRSA active) |
| Anti-tumour | Very early/in vitro only | Various preliminary | Cell apoptosis pathways (early research) |
CBC contributes to the entourage effect — the enhanced therapeutic profile of whole-plant cannabis compared to isolated cannabinoids — through several synergistic interactions:
This is why full-spectrum cannabis products consistently demonstrate superior efficacy vs. isolates in many therapeutic applications: CBC is one of the key minor cannabinoids contributing to that superiority.
CBC is not yet widely analysed and labelled on dispensary menus. Finding high-CBC cultivars requires either lab-tested products with full minor cannabinoid panels or selecting based on known high-CBC genetics.
| Strain / Type | Typical CBC Range | Notes |
|---|---|---|
| Purple Cadillac | ~0.5–1.2% | One of the higher-CBC commercial strains; lab data variable |
| Maui Wowie (Hawaiian phenotypes) | ~0.3–0.8% | Tropical landrace background shows elevated minor cannabinoids |
| Bubba Kush | ~0.2–0.6% | Some phenotypes show notable CBC alongside high myrcene |
| CBC-specific hemp cultivars | 1–5%+ | Specialty hemp bred for minor cannabinoid production; increasingly available |
| Full-spectrum extracts with CoA | Varies | Certificate of Analysis showing minor cannabinoid panel is the gold standard for finding CBC |
